Ketamine impairs the performance of male mice in novel recognition object test and reduces the immunoreactivity of GAD67 in the hippocampus: Role of pioglitazone.
Pharmacology, biochemistry, and behavior February 1, 2025 Talita Rodrigues, Getulio Nicola Bressan, Patrícia Zorzi Juliani et al.
In a mouse model of schizophrenia-like symptoms induced by ketamine, the drug pioglitazone (an activator of PPAR-γ receptors) reversed some of the cognitive and behavioral changes. Ketamine reduced exploration in a novel object recognition test and decreased GAD67 immunoreactivity in the hippocampus. Pioglitazone, given for the last 7 days of a 14-day ketamine regimen, restored performance on the recognition test and normalized hippocampal GAD67 levels. The results suggest that pioglitazone may improve cognitive symptoms associated with schizophrenia, possibly through modulation of GABA-related signaling in the hippocampus.